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decisión desde la perspectiva de un tercer pagador y con tasas de eventos anuales. 
La eficacia de la profilaxis se tomó de la literatura. Los costos incluyeron FVIII, 
hospitalización, consultas por urgencias, colocación y complicaciones del catéter 
venoso central y consultas médicas. La tasa de descuento fue 3% y la utilización de 
recursos se identificó del grupo económico de hemofilia Europeo y se valoró a partir 
de tarifarios locales. La prevalencia de hemofilia se determinó con datos locales. 
Dosis de profilaxis con FVIII: 25U/kg tres veces semanales. Dosis del tratamiento a 
demanda: 40U/kg dos veces diarias por 3,5 días. ResultAdos: En adolescentes de 
10 años y 33kg, la profilaxis con FVIII evitará 118 episodios de sangrado y 47 hemor-
ragias articulares durante el resto de sus vidas, versus a demanda; ICER para el san-
grado fue $6.749 y $17.178 para hemorragias articulares. En adolescentes de 19 años 
y 54kg, la profilaxis con FVIII versus a demanda, evitará 87 episodios de sangrado 
y 34 hemorragias articulares durante el resto de sus vidas; ICER para el sangrado 
fue $11.750 y para hemorragias articulares $29.938. ConClusiones: La profilaxis 
con FVIII es una estrategia costo-efectiva en niños con hemofilia A moderada y que 
presenten 6,4 episodios de sangrado y 2,3 hemorragias articulares, en promedio 
cada año. Si la profilaxis se inicia a una edad más temprana, se prevendrán más 
episodios de sangrado y de hemorragia articular.
PND10
ANálisis De Costo-efeCtiviDAD Dl trAtAmieNto ProfiláCtiCo versus A 
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objeCtivos: La profilaxis con Factor VIII (FVIII) en hemofilia A severa se utiliza 
en países desarrollados, en países en desarrollo hay controversia por sus costos. 
El objetivo de este estudio fue estimar la razón de costo-efectividad incremental 
(ICER) de profilaxis con FVIII versus tratamiento a demanda para prevenir episo-
dios de sangrado y hemorragias articulares en adultos con hemofilia A severa en 
Colombia. MetodologíAs: Se utilizó un árbol de decisión desde la perspectiva del 
tercer pagador y con tasas de eventos anuales. La eficacia de la profilaxis se tomó 
de la literatura. Los costos incluyeron FVIII, hospitalización, consultas por urgen-
cias, colocación y complicaciones del catéter venoso central, consultas médicas y 
días de trabajo perdidos. La tasa de descuento fue 3% y la utilización de recursos 
se identificó del grupo económico de hemofilia Europeo y se valoró a partir de tari-
farios locales. La prevalencia de hemofilia se determinó con datos locales. Dosis de 
profilaxis con FVIII: 25U/kg tres veces semanales. Dosis del tratamiento a demanda: 
50U/kg tres veces diarias por una semana durante la hospitalización y 25U/kg tres 
veces semanales por tres semanas ambulatoriamente. ResultAdos: En adultos 
de 20 años y 70kg, la profilaxis con FVIII evitará 168 episodios de sangrado y 66 
hemorragias articulares durante el resto de su vida, versus a demanda; ICER para el 
sangrado fue $5.676 y $14.463 para hemorragias articulares. En adultos de 40 años 
y 70kg, la profilaxis con FVIII evitará 79 episodios de sangrado y 31 hemorragias 
articulares durante el resto de su vida, versus a demanda; ICER para el sangrado 
fue $5.244 y para hemorragias articulares $13.417. ConClusiones: La profilaxis 
con FVIII en pacientes adultos mejora los resultados clínicos versus a demanda. Si 
la profilaxis se inicia a una edad más temprana, se prevendrán más episodios de 
sangrado y de hemorragia articular.
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objeCtives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect patients. The aim of this study is to conduct a cost-effectiveness analysis of 
natalizumab (Tysabri®) versus glatiramer acetate (Copaxone®) for treatment of 
Relapsing Remitting Multiple Sclerosis (RRMS) patients from the Brazilian Public 
Healthcare System (SUS) perspective. Methods: A Markov model with a 20-year 
time horizon comparing natalizumab to glatiramer acetate was developed. Health 
states were based on EDSS and relapses (moderate or severe). We obtained relapse 
and disability progression transition probabilities from natural history studies 
on RRMS patients. In each monthly cycle, patients can discontinue treatment, 
remain stable, progress to higher MS EDSS state, experience Progressive Multifocal 
Leukoencephalopathy (PML) or die. Patients with EDSS score ≥ 7.5 receive best sup-
portive care. Resource use and costs were validated by an expert’s panel and valued 
using Brazilian public official lists (DATASUS and BPS). Costs and outcomes (5%) were 
discounted. Probabilistic sensitivity analyses (PSA) covered variability in efficacy 
and costs. Results: Use of natalizumab was associated with slower EDSS pro-
gression and reduced relapse burden. The life years gained (LYG) with natalizumab 
and glatiramer acetate was 10.65 and 10.09, respectively. Costs associated with 
natalizumab were USD 119.330 and USD 102.275 for glatiramer acetate. Incremental 
cost-effectiveness rate for natalizumab versus glatiramer acetate was USD 30.251/
LYG. PSA has confirmed the consistency of base case results. ConClusions: For 
a patient with RRMS, this model shows that natalizumab was cost-effective when 
compared to treatment with glatiramer acetate, assuming the threshold of USD 
50.000/LYG commonly mentioned by the Ministry of Health in Brazil.
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objeCtives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect the patient. The aim of this study is to conduct a cost-effectiveness analysis of 
natalizumab (Tysabri®) versus interferon beta-1a (IFNB1a) 44mcg (Rebif®) for treat-
ing Highly Active Relapsing Remitting Multiple Sclerosis (HARRMS) patients. IFNB1a 
yearly frequency and average consumption. Results: The study enrolled 210 MS 
patients, mean age was 40.7 [standard deviation= 11.5] years and 70.7% female. 
Patients with mild disability (according to self-reported Expanded Disability Status 
Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate disability and 15.9% 
had severe disability. The overall yearly direct costs (mean [CI95%]) associated to 
patients with mild, moderate and severe disabilities were: USD18,475 [2,293-34,657], 
USD19,371 [4,651-34,090], and USD19,545 [0-57,659] (1BRL = 0.4937USD), respectively. 
Disease modifying therapies (DMTs) were the major component of the total yearly 
cost, ranging from 93.5% among mild patients to 53.9% in the severe group (85.5% 
in the total sample), followed by aids and home modifications (mild: 2.3%; moder-
ate: 2.3%; severe: 15.1%; total sample: 4.3%). Patients with moderate disability had 
higher absolute costs related to inpatient care, emergency visits, laboratory and 
imaging tests, and DMTs than the other disability groups, while those with severe 
disabilities presented higher costs in the remaining categories (consultations, co-
medications and OTC medications, aids and home modifications, and professional 
caregiver). ConClusions: To our knowledge, this is the first Brazilian study investi-
gating the cost of MS patients. Our findings indicate that MS represent a significant 
economic burden for both the health care system and patients and their families, 
with different expenditures profiles depending on the EDSS level.
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objeCtives: The objective of the study was to assess the cost of MS patients in 
Argentina categorized by disease severity using a societal perspective. Methods: 
This was a cross-sectional study including MS patients from 21 MS centers in 12 
cities of Argentina conducted to collect information on demographics, disease 
characteristics, disease severity, comorbidities, relapses, resource utilization and 
patient reported outcomes, associated with MS. Patients were stratified by dis-
ease severity using the EDSS (group 1 with EDSS score between 0 and 3; group 2 
with EDSS > 3 and < 7; group 3 with EDSS ≥ 7). Direct and indirect costs included 
in the analysis were: inpatient and outpatient care for relapses, inpatient care for 
other reasons than relapses, consultations, investigations, specific MS treatments, 
wheelchair, professional care, informal care, sick leave and retirement due to MS. 
Second quarter 2012 costs were obtained from public sources and converted to US 
Dollars. Results: A total of266 patients were included. 87.6% had relapsing remit-
ting MS. Mean annual cost per MS patient was USD 36,025 (95% CI 31,985-38,068) for 
patients with an EDSS between 0-3; USD 40,705 (95% CI 37,199-46,300) for patients 
with EDSS > 3 and < 7, and USD 50,712 (95% CI 47,825-62,104) for patients with EDSS 
≥ 7. ConClusions: This is the first Argentine study evaluating the costs of MS 
considering disease severity.
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objeCtives: To describe hospital admissions for managing multiple sclerosis (MS) 
relapses in the Brazilian Public Healthcare System (BPHS). Methods: Data from 
the 2009-2012 period were collected from the BPHS Hospital Information System 
(SIH/SUS), which aggregates administrative data from inpatient admissions in public 
hospitals in the entire country. Individual claims coded as “MS Relapse Inpatient 
Treatment” in the SIH/SUS (regardless ICD-10 codes) were identified in the database 
and compiled by state and year. Results: We obtained data on 5,922 individual 
MS relapse-related claims, homegenously distributed among the 4 years. They 
represented an overall cost of BRL3,729,921 for the 2009-2012 period (ranging from 
BRL806,722 in 2010 to BRL1,033,649 in 2012). The 4-year national average cost per 
inpatient admission BRL629, with mean LOS of 7.51 days and ICU days of 0.22. The 
in-hospital mortality rate ranged from 0.65%-1.60%. The 2012 national rate of MS 
relapse-related hospitalization in the general population (per 100,000, absolute num-
ber of admissions / total population) was 0.79, varying from 0.03/100,000 in Alagoas 
(Northeast region) to 1.78/100,000 in Santa Catarina (South region). All parameters 
were consistently different among Brazilian states. In-hospital deaths were very rare 
in this sample not allowing robust conclusions. It was possible to identify significant 
outliers in the mean cost per admission when states were separately considered (2012 
data: from BRL323 [n= 3] in Sergipe to BRL 4,596 in Espírito Santo [n= 4]). São Paulo was 
the state with higher absolute number of hospitalizations in all years. In 2012, the 
state had 526 admissions, mean cost per event of BRL810, 4 in-hospital deaths (0.76%), 
mean LOS= 6.16, and mean ICU days of 0.36. ConClusions: BPHS administrative 
hospital database can provide insightful information about MS relapse-related admis-
sions. Both geographical and time trends can be examined using SIH/SUS secondary 
data, particularly for diseases with highly specific procedure codes.
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objeCtivos: Algunos adolescentes con hemofilia A moderada reciben profilaxis 
con Factor VIII (FVIII), pero los resultados económicos de esta estrategia de tratami-
ento son desconocidos. El objetivo de este estudio fue estimar la razón de costo-
efectividad incremental (ICER) de profilaxis con FVIII versus tratamiento a demanda 
para prevenir episodios de sangrado y hemorragias articulares en adolescentes 
con hemofilia A moderada en Colombia. MetodologíAs: Se utilizó un árbol de 
